louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03376425: Transthoracic Shear-wave Ultrasound Elastography
Official title: Application of Transthoracic Shear-wave Ultrasound Elastography in the Diagnosis of Pulmonary Lesions
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Elasticity Imaging Techniques
Keywords: Chest ultrasound,Lung tumor
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2017-12-18
Enrollment: 2000
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients receiving chest ultrasonography in National Taiwan University Hospital

Brief summary: This study aims to provide the information of tissue elasticity in different etiologies of pulmonary lesions and to validate the predictive value of shear-wave elastography in differentiating benign pulmonary lesions from malignant lesions.


Eligibility criteria: 1. Inclusion criteria: (1) Retrospective cohort from Jan 2016 to Dec 2017 (2) Patients with radiographic evidence of pulmonary tumors
2. Exclusion criteria: (1) age \< 20 y/o (2) patients who can't hold their breath for 5 seconds

Primary outcomes:
measure: Application of Transthoracic Shear-wave Ultrasound Elastography in the Diagnosis of Pulmonary Lesions
timeFrame: six months
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yao-Wen Kuo, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kuo YW, Chen YL, Wu HD, Chien YC, Huang CK, Wang HC. Application of transthoracic shear-wave ultrasound elastography in lung lesions. Eur Respir J. 2021 Mar 25;57(3):2002347. doi: 10.1183/13993003.02347-2020. Print 2021 Mar.
Clinical trial NCT01955525: Long-term Follow-up of Health Related Quality of Life in Patients With Acute Coronary Syndrome
Official title: Long-term Follow-up of Health Related Quality of Life in Patients Hospitalised With Acute Coronary Syndrome: Evaluation of the Methods and Management of Acute Coronary Events (EMMACE)-3X
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Coronary Syndrome
Keywords: Acute coronary syndrome
health related quality of life
mortality
Lead sponsor: University of Leeds
Sponsor class: OTHER
First posted: 2013-10-07
Enrollment: 3500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who have been hospitalised with an ACS during the period of 2011 to 2013 and took part in EMMACE3 study(REC number 10/H1313/74)

Brief summary: This study is aiming to i)measure longterm health related quality of life (HRQL) outcomes of the EMMACE3 patients hospitalised with acute coronary syndromes (ACS) and evaluate possible associations with their cardiovascular profile and to ii) Linkage these data to multiple electronic healthcare records

Detailed description: Over the last few years the chance of dying from a heart attack in England and Wales has reduced dramatically. Even so, there remain huge differences in mortality between hospitals. For example, up to a third of patients with a heart attack who attend hospitals in England are more likely to die than would be expected. That is, the type of treatment and the risk of death depend upon where a patient lives and which hospital they attend. In part, the variation in death may be due to the services available at the hospital or to factors such as socioeconomic deprivation. It may also relate to other factors such as depression, cardiac rehabilitation, patient experience of hospital care and health quality of life.

Using statistical approaches that include measures of quality of life, we propose to examine data about heart attacks in England and investigate the 'postcode lottery of care'. This research is a long term followup that promote improved patient care. In doing so, different factors affecting cardiac rehabilitation will be highlighted and healthcare policy changed so that all patients will have an equal chance of surviving a heart attack.

Eligibility criteria: Inclusion Criteria:

* Age\>=18 years, both sexes, acute admission to hospital in England with an ACS, consented to participate in EMMACE3 study

Exclusion Criteria:

* Those in whom follow up would be inappropriate or impractical (for example patients in the terminal stages of an illness or requiring emergency treatment such that the gathering research data is not possible or appropriate.

Primary outcomes:
measure: Health related quality of life
timeFrame: 10 years
Secondary outcomes:
measure: Mortality
timeFrame: 10 years
Other outcomes:
Locations:
city: Leeds
country: United Kingdom
facility: University of Leeds
state: West Yorkshire
Study officials:
References:
Clinical trial NCT00658125: Deep Brain Stimulation (DBS) for Alzheimer's Disease
Official title: Modulation of Cognitive Function Using Electrical Brain Stimulation in Patients With Early Alzheimer Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alzheimer Disease
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2008-04-14
Enrollment: 6
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Background: Alzheimer disease (AD) is a debilitating brain disorder that affects over 4.75 million people in the US and Canada. People with AD have difficulty remembering general facts and previously experienced autobiographical events. Animal and human research demonstrates that this type of memory depends on neural function within specific brain areas, and that it may be possible to enhance memory with electrical stimulation of these brain areas. We have recently shown that deep brain stimulation (DBS) of a brain area called the fornix enhances memory in a human.

Hypotheses: We hypothesize that fornix DBS will safely enhance memory in early AD patients by activating memory circuits in the brain.

Methods: Six early AD patients will take part in a phase I clinical study over a 1-year period. The study involves bilateral fornix DBS implantation, detailed neuropsychological and neurological testing, and brain imaging to detect alterations in brain activity induced by stimulation. These assessments will occur one month before surgery, then again at one month, 6 months, and 12 months after surgery.


Eligibility criteria: Inclusion Criteria:

* Men and women aged 40 to 80 years old, who
* Satisfy the diagnostic criteria for probable AD,
* Have received the diagnosis of AD within the past 2 years,
* Have a CDR of 0.5 or 1.0, and
* Score between 20 and 28 on the Mini Mental State Examination

Exclusion Criteria:

* Pre-existing structural brain abnormalities,
* Other neurologic or psychiatric diagnoses, or
* Medical comorbidities that would preclude them from undergoing surgery

Primary outcomes:
measure: memory performance on neuropsychological tests
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto Western Hospital
state: Ontario
Study officials:
affiliation: Toronto Western Research Institute
name: Adrian W Laxton, MD
role: STUDY_DIRECTOR
affiliation: Toronto Western Research Institute
name: Andres M Lozano, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Toronto Western Research Institute
name: David Tang-Wai, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hamani C, McAndrews MP, Cohn M, Oh M, Zumsteg D, Shapiro CM, Wennberg RA, Lozano AM. Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann Neurol. 2008 Jan;63(1):119-23. doi: 10.1002/ana.21295.
Clinical trial NCT00333125: A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Glaucoma
Ocular Hypertension
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2006-06-02
Enrollment: 319
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the intraocular pressure (IOP)-lowering efficacy and safety of two combination products in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria: Inclusion Criteria:

* 18 or older.
* Diagnosis of glaucoma or ocular hypertension.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Under 18.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Mean Intra-Ocular Pressure (IOP)
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Saeed M, Kadir S, Kaufman SL, Murray RR, Milligan F, Cotton PB. Bleeding following endoscopic sphincterotomy: angiographic management by transcatheter embolization. Gastrointest Endosc. 1989 Jul-Aug;35(4):300-3. doi: 10.1016/s0016-5107(89)72796-6.
Clinical trial NCT05069025: Use of Music in Reducing Pain During Outpatient Hysteroscopy in Primarily Infertile Patients
Official title: Use of Music in Reducing Pain During Outpatient Hysteroscopy in Primarily Infertile Patients: Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hysteroscopy
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Hospital El Gezeera
First posted: 2021-10-06
Enrollment: 130
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to demonstrate the value of music in outpatient hysteroscopy on patients' level of pain and satisfaction in primarily infertile patients.


Eligibility criteria: Inclusion Criteria:

* women with primary infertility requiring a diagnostic hysteroscopy as a part of an infertility diagnosis workup

Exclusion Criteria:

* women with suspected pregnancy

heavy vaginal bleeding recent pelvic infection those who received analgesics prior to OH a concomitant neurologic disease that could affect the correct evaluation of pain

Primary outcomes:
measure: Intensity of pain
timeFrame: 5 minutes
Secondary outcomes:
measure: Intensity of pain
timeFrame: 30 minutes
measure: women satisfaction
timeFrame: 30 minutes
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00954525: Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer
Official title: Phase I, Open Label, Dose Escalating Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Metastatic Pancreatic Cancer
Keywords: Pancreatic Cancer
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2009-08-07
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Eligible candidates will be adults with metastatic pancreatic cancer (confirmed diagnosis with pathology reports and measurable computed tomography (CT) or magnetic resonance imaging (MRI)). Participants must not be receiving any other concurrent chemotherapy, or radiation therapy. Full inclusion/exclusion criteria are available. History and physical examination, and laboratory and imaging analyses will be done within 14 days prior to registration. The three cohorts of subjects will receive 50, 75 or 100 grams of intravenous ascorbic acid, three times per week for 8 weeks. Subjects will also have co-administration of the chemotherapy medications, gemcitabine (intravenously) and erlotinib (orally). Approximately 9 to 18 participants will be enrolled in this Phase I study.


Eligibility criteria: Inclusion Criteria:

* Metastatic pancreatic cancer
* Glucose 6 phosphate dehydrogenase status normal
* ECOG performance status 0-2
* Normal creatinine and transaminase
* Women of child-bearing potential confirm negative pregnancy test

Exclusion Criteria:

* Concurrent chemotherapy or radiotherapy
* Significant co-morbid disorders
* Significant psychiatric symptoms
* Prior treatment with gemcitabine
* Concurrent chronic use of immunosuppressive agents (methotrexate, cyclosporine,corticosteroids)
* Regular use of nonsteroidal anti-inflammatory agents
* Smoking more than 1 pack per day
* Excessive alcohol or drug use
* Enrollment in other experimental therapy
* Active infection
* Patients experiencing ongoing response to recent treatments

Primary outcomes:
measure: Safety, assessed by toxicity (graded by NCI CTC), urinalysis, ECG, basic metabolic panel, CBC, and osmolality.
timeFrame: 8 weeks
Secondary outcomes:
measure: Progression-free survival
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Jefferson-Myrna Brind Center of Integrative Medicine
state: Pennsylvania
Study officials:
affiliation: Sidney Kimmel Cancer Center at Thomas Jefferson University
name: Daniel Monti, MD, MBA
role: PRINCIPAL_INVESTIGATOR
References:
citation: Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794. doi: 10.1371/journal.pone.0029794. Epub 2012 Jan 17.
Clinical trial NCT05101525: Study of the Functional Result of the Reinsertion of the Subscapular in Reverse Shoulder Prostheses According to the Healing of the Subscapular
Official title: Study of the Functional Result of the Reinsertion of the Subscapular in Reverse Shoulder
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Reverse Shoulder Prothesis
Healing of the Subscapularis
Lead sponsor: Ramsay Générale de Santé
Sponsor class: OTHER
Collaborators: name: European Clinical Trial Experts Network
First posted: 2021-11-01
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study is based on the hypothesis that the functional result is better if the subscapularis is reinserted and healed. The originality of the study therefore consists in systematically monitoring the healing of this tendon postoperatively, with sufficient follow-up, by ultrasound and by an intra-tendon marker, in order to differentiate the result depending on whether the tendon is healed or not.


Eligibility criteria: Inclusion Criteria:

* Men or women over 18 years old
* Patient with an indication of reverse prosthesis for cuff rupture, or eccentric omarthrosis, or omarthrosis without cuff rupture but with posterior eccentricity
* Patient with a normal subscapularis preoperatively
* Patient benefiting from a social protection insurance
* Patient having signed the free and informed consent

Exclusion Criteria:

* Patient with an indication of anatomical prosthesis
* Patient with an abnormal subscapularis preoperatively
* Patient operated for a revision of prosthesis
* Patient with an indication for prosthesis on fracture sequelae
* Patient with an indication for prosthesis on fracture
* Patient participating in another clinical study
* Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
* Pregnant, breastfeeding or parturient woman
* Patient hospitalized without consent.

Primary outcomes:
measure: Mobility of internal rotation evaluation
timeFrame: 12 months
measure: Tendon healing assessment
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Caen
country: France
facility: Saint Martin Private Hospital
state: Normandy
Study officials:
References:
Clinical trial NCT00155025: Family History in Prostate Cancer Patients in Taiwan
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Prostate Cancer
Keywords: Prostatic neoplasms
Family history
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-12
Enrollment: 1500
Sex: MALE
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: To investigate the prevalence of family history in prostate cancer patients in Taiwan and evaluate the association of variation of diseases and family history

Detailed description: We retrospectively reviewed the medical charts of prostate cancer patients at NTUH from 1978 to 2002. The initial presentations, systemic diseases, smoking habits, clinical stages, Gleason scores, pathological stages, treatments, and outcome were recorded. Post-hoc questionnaires were completed with OPD visits, admission visits, telephone interviews and mails. The questionnaires included the family histories of prostate cancer, colon cancer, breast cancer, hepatoma and so on. If patients is passed away, the first degree relatives will fill the vacant position. The prevalence of family histories of prostate cancers in these patients was determined. The associations of family histories and clinical presentations were analyzed. Besides, the characteristics of patients with and without responses were discussed.

Eligibility criteria: Inclusion Criteria:

* Prostate cancer patients who were recorded at National Taiwan University Hospital from 1977 to 2002.

Exclusion Criteria:

* Patients or their family who refused our contact or were unable to be contacted

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yeong-Shiau Pu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05921825: Red Cell Distribution Width and Lactate Albumin Ratio as Prognostic Markers for Mortality in Sepsis and Septic Shock
Official title: Red Cell Distribution Width and Lactate Albumin Ratio as Prognostic Markers for Mortality in Sepsis and Septic Shock Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Morality
Sepsis
Septic Shock
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2023-06-27
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients of both sex with age between (18:60) years old admitted to surgical intensive care unit suffering from sepsis or septic shock will be enrolled in the study after fulfillments of inclusion and exclusion criteria.

Brief summary: The aim of this study is to find the utility of red cell distribution width and lactate/albumin ratio as prognostic markers in sepsis and septic shock patients.

Detailed description: Several indicators are being used to predict the prognosis of sepsis. Commonly used prognostic indicators include Acute Physiological and chronic health evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA), Mortality in Emergency Department Score (MEDS), New York Sepsis severity score.

Red cell distribution Width and lactate albumin ratio are being investigated for there prognostic value in septic patients.

Eligibility criteria: Inclusion Criteria:

1. Age from 18 to 60 years old.
2. Clinical criteria of sepsis
3. Or clinical criteria of septic shock including sepsis with persisting hypotension requiring vasopressors to maintain mean arterial pressure \> 65 mmHg and having a serum lactate level \> 2 mmol/L despite adequate volume resuscitation.

Exclusion Criteria:

1. No informed consent.
2. Patient with incomplete information and data.
3. The patient who received blood transfusion within 90 days before emergency admission.
4. The patients who are known to have long-term conditions causing anemia like sickle cell anemia, thalassemia, iron deficiency anemia.
5. Malignancy and chemotherapy during the previous 90 days.
6. Patients with either hepatic dysfunction, renal failure, having any disease in which albumin should be supplemented as liver cirrhosis with ascites, nephrotic syndrome and burns.

Primary outcomes:
measure: The prediction of mortality
timeFrame: 28 days
Secondary outcomes:
measure: Length of intensive care stay
timeFrame: 28 days or till discharge from intensive care.
measure: Extent of organ dysfunctions in patients with severe sepsis and septic shock
timeFrame: 28 days
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University Hospitals
state: Elgharbia
Study officials:
References:
Clinical trial NCT06414525: Effect of Abdominal Massage Versus Visceral Manipulation on Constipation
Official title: Effect of Abdominal Massage Versus Visceral Manipulation on Constipation Status and Quality of Life in Adults
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Constipation Chronic Idiopathic
Keywords: chronic idiopathic constipation
abdominal massage
visceral manipulation
quality of life
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-05-16
Enrollment: 75
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study compares the effect of abdominal massage vs. visceral manipulation on constipation status and quality of life in adults.

Chronic idiopathic constipation (CIC) is considered a common functional bowel disorder characterized by difficult, infrequent, and/or incomplete defecation. It has a great impact on the quality of life and on the healthcare system and represents an important financial strain .


Eligibility criteria: Inclusion Criteria:

* Patients of both sex with age ranges (20-40) years old.
* having a diagnosis of functional constipation according to Rome IV criteria onset of constipation symptoms from 6-12 months .
* having body mass index 18.5-29.9 kg/m2 , waist height ratio \</=0.5
* Subjects bothered by their constipation

Exclusion Criteria:

* Pregnancy.
* Having comorbidities (chronic pelvic pain, neurological (Parkinson's, multiple sclerosis, spinal cord lesion, etc.), metabolic / endocrine (diabetes mellitus, hypercalcemia, hypothyroid, etc.), cardiorespiratory diseases
* Health problems which may prevent standing from sitting, walking (orthopedic, neurological, cardiorespiratory, etc.)
* Malignancy, acute inflammation, intestinal tumor
* History of gastrointestinal and pelvic surgery or spinal surgery other than cholecystectomy, appendectomy, or hysterectomy
* Visual, auditory or cognitive problems which may prevent participation to the study.
* Tumor, presence of skin problems in the application area
* Presence of laxative use for functional constipation in the last four weeks or patients on laxative therapy.
* Alarm symptoms (unexplained, more than 10% weight loss in 3 months, hemorrhoids and anal fissures, rectal bleeding, family history of colon cancer)

Primary outcomes:
measure: Constipation Severity Instrument (CSI)
timeFrame: 6 weeks
measure: Constipation Assessment Scale
timeFrame: 6 weeks
measure: Patient Assessment of Constipation- Quality of Life (PAC-QOL) Questionnaire
timeFrame: 6 weeks
measure: Bowel Function Index
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Ismailia
country: Egypt
facility: Abo Khalefa emergency hospital
Study officials:
References: